GENINCODE PLC (GENI) — Full year results briefing

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the GENINCODE PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press end. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review your questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. And I'd now like to hand you over to Matthew Walls, CEO. Good afternoon, sir. Good afternoon, Lily. Thank you for that. Good good afternoon, everyone. Welcome to the annual results presentation. My name is Matthew Walls, CEO of GENINCODE. I'm here with Paul Fulger in the offices of Cavendish in the city. I'm gonna walk through this fairly swiftly, but it'll give us time to have a q and a towards the end. So and also for, hopefully, those who are are attending, I think many of you have maybe heard some of the the prelude in the early slides previously. So I'll move with a little bit of pace. The company is focused on the prevention of heart disease. We're in a process of scaling up, expanding, and growing the company certainly in terms of revenue. So we're not involved in heavy investments in development, research and development, and so on. Our core products are regulatory approved with a key product, CARDIONCODE, going through regulatory approval with the FDA. We have a significant amount of investment over the last ten, fifteen years now in building out what we do as a company, the structures for risk scoring and recognizing genetic risk for heart disease. We have a leading ev...